A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Latest Information Update: 09 Sep 2019
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 09 Sep 2019 Status changed to discontinued.
- 19 Feb 2018 Status changed from active, no longer recruiting to completed.
- 23 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 9 May 2018.